Theravance Biopharma Q3 2023 GAAP EPS $(0.17) Beats $(0.21) Estimate, Sales $15.69M Beat $15.00M Estimate
Portfolio Pulse from saritha@benzinga.com
Theravance Biopharma reported Q3 2023 GAAP EPS of $(0.17), beating the estimate of $(0.21) by 19.05%. The company also reported quarterly sales of $15.69M, surpassing the estimate of $15.00M by 4.62%. Both figures represent an increase from the same period last year.
November 07, 2023 | 10:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theravance Biopharma's Q3 2023 results exceeded estimates, with EPS and sales both showing an increase from the same period last year.
Theravance Biopharma's better-than-expected Q3 2023 results, with both EPS and sales beating estimates and showing an increase from the same period last year, are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100